WHO said in a statement on Saturday.For each of the drugs, the interim results do not provide solid evidence of increased mortality.
There were, however, some associated safety signals in the clinical laboratory findings of the add-on Discovery trial, a participant in the Solidarity trial.
These will also be reported in the peer-reviewed publication.This decision applies only to the conduct of the Solidarity Trial in hospitalized patients and does not affect the possible evaluation in other studies of hydroxychloroquine or lopinavir/ritonavir in non-hospitalized patients or as pre- or post-exposure prophylaxis for covid-19, the WHO said.Of 6,71,680 cases reported in India till Saturday, 2,35,433 are active.